Vir Biotechnology (VIR) Return on Invested Capital (2019 - 2025)

Vir Biotechnology (VIR) posted Return on Invested Capital of 0.19% for Q4 2025, down 14.86% sequentially from 0.16% in Q3 2025.

Vir Biotechnology (VIR) Return on Invested Capital (2019 - 2025) Analysis & Trends

Vir Biotechnology has reported Return on Invested Capital for 5 years, with the latest figure at 0.19% in Q4 2025.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.19% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.19% (changed N/A YoY) and the FY2020 annual result came in at 0.32%, changed N/A from the prior year.
Return on Invested Capital slipped to 0.19% in Q4 2025 per VIR's latest filing, from 0.16% in the prior quarter.
Over five years, Return on Invested Capital peaked at 0.13% in Q2 2022 and troughed at 0.26% in Q1 2025.
A 3-year average of 0.07% and a median of 0.06% in 2021 frame the typical range for Return on Invested Capital.
The sharpest annual moves came in 2021 and 2022: Return on Invested Capital grew 3 bps in 2021, then grew 18 bps in 2022.
Over 3 years, Return on Invested Capital stood at 0.03% in 2021, then soared by 295 bps to 0.13% in 2022, then slumped by 246 bps to 0.19% in 2025.
According to Business Quant data, Return on Invested Capital over the past three periods registered 0.19%, 0.16%, and 0.18% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.04%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.05%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.35%
10	Vir Biotechnology	1.56 Bn	1.56 Bn	238.95 Mn	-

Download Data